{"id":"1dc36d7595b5","type":"article","url":"https://hartvaat.nl/2027/01/01/glp-1-agonisten-verlagen-atriumfibrilleren-bij-patienten-met-obesitas-en-nierins/","title":"GLP-1-agonisten verlagen atriumfibrilleren bij patiënten met obesitas en nierinsufficiëntie","title_en":"GLP-1 receptor agonist therapy and incident atrial fibrillation in non-diabetic adults with obesity and chronic kidney disease: a propensity matched cohort study.","category":"preventie","category_label":"Preventie","professions":["cardioloog","huisarts","internist"],"tags":[],"journal":"International journal of cardiology","doi":"10.1016/j.ijcard.2026.135000","source_url":"https://doi.org/10.1016/j.ijcard.2026.135000","authors":["Abdulraheem Hassan","Efeturi Okorigba","Chilaka Grace","Emmanuel Otabor","Busayo Osineye","Olalekan Olayiwola","Tutuola Oyeleye","Parthiv Amin"],"significance":6,"published":"2026-11-21","source_date":"2027-01-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"A propensity-matched cohort study of over 7,000 patients demonstrates that GLP-1 receptor agonists reduce the 1-year incidence of atrial fibrillation by 35% in non-diabetic adults with obesity and chronic kidney disease. Benefits extended to ventricular tachyarrhythmias and all-cause hospitalizations, with consistent effects across 1- to 3-year follow-up. These real-world findings highlight a potential cardiorenal advantage of GLP-1 therapy and underscore the need for dedicated randomized trials in this high-risk phenotype.","created":"2026-11-15T01:51:14Z","updated":"2026-11-15T01:51:14Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een retrospectieve cohortstudie met meer dan 7.000 gematchte patiënten toont aan dat GLP-1-agonisten het risico op incident atriumfibrilleren met 35% verlagen bij niet-diabetische volwassenen met obesitas en chronische nierinsufficiëntie. Ook ventriculaire tachyarrhythmieën en ziekenhuisopnames namen significant af, met consistente resultaten over 1 tot 3 jaar follow-up. Deze bevindingen ondersteunen het cardiorenale profiel van GLP-1-remmers en onderstrepen de noodzaak van gerandomiseerde trials in deze specifieke populatie.","abstract_original":"BACKGROUND: Obesity and chronic kidney disease (CKD) are potent risk factors for atrial fibrillation (AF), yet whether GLP-1 receptor agonists (GLP-1RAs) prevent incident AF in non-diabetic adults with obesity and CKD is unexamined. We assessed whether GLP-1RA therapy reduces 1-year AF incidence in this cardiorenal phenotype. METHODS: Using the TriNetX US Collaborative Network (66 healthcare organizations), we conducted a retrospective target trial emulation of non-diabetic adults aged 18 or older with obesity and CKD stages 3-5 diagnosed 2021-2024. Patients receiving semaglutide, liraglutide, or tirzepatide (n = 10,985) were compared with unexposed patients (n = 94,527). After propensity score matching, 7326 patients remained per cohort. The primary outcome was incident AF at 1 year; secondary outcomes included AF subtypes, ventricular tachyarrhythmias, and all-cause hospitalization. Cox models generated hazard ratios (HRs); sensitivity analyses extended follow-up to 2-3 years with landmark analyses. RESULTS: At 1 year, GLP-1RA use was associated with significantly lower incident AF (1.63% vs. 2.62%; HR 0.655, 95% CI 0.508-0.844; p = 0.001), a 34.5% relative risk reduction. Reductions were consistent for paroxysmal (HR 0.586), persistent (HR 0.482), and longstanding persistent AF (HR 0.527; all p < 0.05); permanent AF was non-significant at 1 year. Ventricular tachyarrhythmias (HR 0.556; p = 0.002) and hospitalization (HR 0.668; p < 0.001) were also significantly reduced. Benefits persisted across 2- and 3-year follow-up and remained consistent in landmark analyses. CONCLUSIONS: In non-diabetic adults with obesity and CKD, GLP-1RA therapy was associated with significant, durable reductions in incident AF, ventricular arrhythmias, and hospitalization. These findings are consistent with a possible cardiorenal benefit and support prioritizing this phenotype for dedicated randomized trials."}